IP Library Granted Patent US 12,325,864
Granted Patent B2
US 12,325,864 · App. 18/158,852 · Granted Jun 10, 2025

Recombinant virus vector (RVV) for inhibiting epidermal growth factor receptor (EGFR) activity and method of making an agent/target cell complex to increase cetuximab-like protein (CLP) production

Inventor: Bradley G. Thompson (Calgary, CA)
Assignee: Kinase Pharma Inc.
C12N15/86C07K16/2863A61K48/00C07K2317/24C12N2330/50C12N2750/14143
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,325,864
App. No.
18/158,852
Granted
Jun 10, 2025
Kind
B2
Abstract

The present disclosure relates to one or more agents, therapies, treatments, and methods of use of the agents and/or therapies and/or treatments for increasing production of a Cetuximab-like protein (CLP) by a subject that is administered the agent, therapy or treatment. Embodiments of the present disclosure can be used as a therapy or a treatment for a subject that has a condition that may benefit from reducing the DNA synthesis of genes that regulate cellular growth and proliferation.

Claims (7)

1. A recombinant virus vector (RVV), the RVV comprising

a nucleotide sequence encoding for production of a cetuximab-like protein (CLP), wherein the nucleotide sequence comprises SEQ ID No: 1, SEQ ID No: 2, SEQ ID No: 3, SEQ ID No: 4, SEQ ID No.5, SEQ ID No: 6, SEQ ID No. 7 and SEQ ID No. 8,

wherein the RVV is an adeno-associated virus vector and wherein the CLP can bind to and inhibit the activity of Epidermanl Growth Factor Receptor (EGFR).

2. The RVV of claim 1 , wherein the inhibited activity of the EGFR is EGFR-mediated dysregulation of DNA synthesis of genes that relate to cell growth and proliferation in tumor cells.

3. A pharmaceutical composition comprising the RVV of claim 1 and one or more pharmaceutically acceptable carriers and/or one or more excipients.

4. A method of making an agent/target cell complex, the method comprising a step of administering an adeno-associated virus (AAV) to a target cell for forming the agent/target cell complex, wherein the agent/target cell complex causes the target cell to increase production of a cetuximab-like protein (CLP), wherein the AAV comprises the nucleotide sequence according to SEQ ID No. 9 for increasing the target cell's production of the CLP.

5. The method of claim 4 , wherein the target cell is one or more of an adrenal gland cell; a bile duct cell; a chondrocyte; a cochlear cell; a corneal cell; an endocardium cell; an endometrial cell; an endothelial cell; an epithelial cell; a fibroblast; a hair follicle cell; a hepatocyte; a lymph node cell; a mucosal cell; a myocyte; a neuron; a glomeruli cell; an optic nerve cell; an osteoblast; an ovarian tissue cell; a pancreatic islet beta cell; a pericardium cell; a platelet; a red blood cell (RBC); a retinal cell; a scleral cell; a Schwann cell; a T cell; a testicular tissue cell; a thyroid gland cell; a uveal cell; a tumor cell, and combinations thereof.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jan 24, 2023
From: THOMPSON, BRADLEY G.
To: KINASE PHARMA INC.
Reel/Frame 062471/0405 →
Continuity (2)
Continuation 17313801 · May 6, 2021
Related Publication 20230340533A1 · Oct 26, 2023
References Cited (15)
US 6764845B2 · Sista · 2004 [cited by examiner]
US 8367069B2 · Ferris · 2013 [cited by applicant]
US 9163259B2 · Choi · 2015 [cited by examiner]
US 10494645B2 · Auricchio et al. · 2019 [cited by applicant]
Xing M, et al. (Apr. 5, 2016) Oncotarget. 7(19):28262-28272. [cited by examiner]
Yan Z, et al. (Jan. 2005) Journal of Virology. 79(1):364-379. (doi:10.1128/JVI.79.1.364-379.2005). [cited by examiner]
Paul, WE (1993) Fundamental Immunology, 3rd ed. Raven Press, NY, Chap. 9, pp. 292-295. [cited by examiner]
Rudikoff, S et al. (1982) Proc. Natl. Acad. Sci. USA, 79:1979-1983 (doi: 10.1073/pnas.79.6.1979). [cited by examiner]
Colman, PM (1994) Research in Immunology, Elsevier, NY, 145(1):33-36. [cited by examiner]
Bendig M. M. (1995) Methods: A Companion to Methods in Enzymology, 8:83-93. [cited by examiner]
MacCallum et al. (Oct. 11, 1996) J. Mol. Biol., 262(5):732-745. (doi: 10.1006/jmbi.1996.0548). [cited by examiner]
Casset et al (2003) Biochemical and Biophysical Research Communications, 307:198-205. (doi:10.1016/S0006-291X(03)01131-8). [cited by examiner]
Chen et al. (1995) EMBO J., 14(12):2784-2794. (doi: 10.1002/j.1460-2075.1995.tb07278.x). [cited by examiner]
Wang D, et al. (May 2018). Nature Reviews Drug Discovery 18:358-378. (https://dol.org/10.1038/s41573-019-0012-9). [cited by applicant]
Wilmott P, et al. (2019). Human Gene Therapy Methods 30(6):206-213. (DOI: 10.1089/hgtb.2019.276). [cited by applicant]